JP2021504446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504446A5 JP2021504446A5 JP2020545063A JP2020545063A JP2021504446A5 JP 2021504446 A5 JP2021504446 A5 JP 2021504446A5 JP 2020545063 A JP2020545063 A JP 2020545063A JP 2020545063 A JP2020545063 A JP 2020545063A JP 2021504446 A5 JP2021504446 A5 JP 2021504446A5
- Authority
- JP
- Japan
- Prior art keywords
- nanobiological
- composition
- composition according
- accelerator
- phosphocholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 7
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 3
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 229930182558 Sterol Natural products 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000002077 nanosphere Substances 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- VXUOFDJKYGDUJI-OAQYLSRUSA-N 1-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-OAQYLSRUSA-N 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- -1 fatty acid esters Chemical class 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims 1
- SVWBXNAUENUONE-LDLOPFEMSA-N 1-hexadecanoyl-2-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCO[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC SVWBXNAUENUONE-LDLOPFEMSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 229920002498 Beta-glucan Polymers 0.000 claims 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000712 assembly Effects 0.000 claims 1
- 238000000429 assembly Methods 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 108010025838 dectin 1 Proteins 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 102000051062 human APOA1 Human genes 0.000 claims 1
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims 1
- 239000002107 nanodisc Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 229940121343 tricaprilin Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical group CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023130072A JP7772748B2 (ja) | 2017-11-21 | 2023-08-09 | 治療用ナノ生物学的組成物による訓練免疫の促進 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589054P | 2017-11-21 | 2017-11-21 | |
| US62/589,054 | 2017-11-21 | ||
| PCT/US2018/061935 WO2019103998A2 (en) | 2017-11-21 | 2018-11-20 | Promoting trained immunity with therapeutic nanobiologic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130072A Division JP7772748B2 (ja) | 2017-11-21 | 2023-08-09 | 治療用ナノ生物学的組成物による訓練免疫の促進 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021504446A JP2021504446A (ja) | 2021-02-15 |
| JP2021504446A5 true JP2021504446A5 (enExample) | 2022-01-04 |
| JPWO2019103998A5 JPWO2019103998A5 (enExample) | 2023-05-23 |
| JP7330994B2 JP7330994B2 (ja) | 2023-08-22 |
Family
ID=66630773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545063A Active JP7330994B2 (ja) | 2017-11-21 | 2018-11-20 | 治療用ナノ生物学的組成物による訓練免疫の促進 |
| JP2023130072A Active JP7772748B2 (ja) | 2017-11-21 | 2023-08-09 | 治療用ナノ生物学的組成物による訓練免疫の促進 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130072A Active JP7772748B2 (ja) | 2017-11-21 | 2023-08-09 | 治療用ナノ生物学的組成物による訓練免疫の促進 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20200253884A1 (enExample) |
| EP (1) | EP3713548A4 (enExample) |
| JP (2) | JP7330994B2 (enExample) |
| CN (1) | CN111971028A (enExample) |
| AU (2) | AU2018370828B2 (enExample) |
| CA (1) | CA3082830A1 (enExample) |
| WO (1) | WO2019103998A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077439A (zh) | 2016-04-29 | 2023-05-09 | 西奈山伊坎医学院 | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 |
| WO2021263188A1 (en) * | 2020-06-25 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Live cell engagement assay |
| US11859021B2 (en) * | 2021-03-19 | 2024-01-02 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| IT202100014747A1 (it) * | 2021-06-07 | 2022-12-07 | Consiglio Nazionale Ricerche | Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore |
| IL309578A (en) | 2021-06-22 | 2024-02-01 | Bio Trip B V | Nanoparticles containing nucleic acid |
| CA3258109A1 (en) | 2022-06-03 | 2023-12-07 | Bio-Trip B.V. | LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101096386A (zh) * | 2007-06-05 | 2008-01-02 | 复旦大学 | Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用 |
| WO2009051451A2 (en) * | 2007-10-17 | 2009-04-23 | Korea Advanced Institute Of Science And Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| US20110020242A1 (en) * | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| WO2012026712A2 (ko) * | 2010-08-23 | 2012-03-01 | 주식회사 강스템홀딩스 | Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| EP3273944B1 (en) * | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2016197067A1 (en) * | 2015-06-05 | 2016-12-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy |
| US20180221289A1 (en) * | 2015-08-06 | 2018-08-09 | Autotelic Llc | Phospholipid-cholesteryl ester nanoformulations and related methods |
-
2018
- 2018-11-20 EP EP18880348.0A patent/EP3713548A4/en active Pending
- 2018-11-20 WO PCT/US2018/061935 patent/WO2019103998A2/en not_active Ceased
- 2018-11-20 CA CA3082830A patent/CA3082830A1/en active Pending
- 2018-11-20 CN CN201880086231.5A patent/CN111971028A/zh active Pending
- 2018-11-20 AU AU2018370828A patent/AU2018370828B2/en active Active
- 2018-11-20 JP JP2020545063A patent/JP7330994B2/ja active Active
-
2020
- 2020-04-30 US US16/862,564 patent/US20200253884A1/en not_active Abandoned
- 2020-04-30 US US16/862,570 patent/US20200261591A1/en not_active Abandoned
-
2022
- 2022-12-07 US US18/076,759 patent/US20230355537A1/en not_active Abandoned
-
2023
- 2023-08-09 JP JP2023130072A patent/JP7772748B2/ja active Active
-
2024
- 2024-10-25 US US18/927,572 patent/US20250268839A1/en active Pending
-
2025
- 2025-02-21 AU AU2025201252A patent/AU2025201252A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504446A5 (enExample) | ||
| Zhu et al. | CaCO3-assisted preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy | |
| Yu et al. | Near-infrared photoactivatable semiconducting polymer nanocomplexes with bispecific metabolism interventions for enhanced cancer immunotherapy | |
| Zhang et al. | Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis | |
| Shahzad et al. | Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles | |
| KR101839864B1 (ko) | 암을 치료하는 방법 | |
| Pan et al. | Mesoporous silica nanoparticles (MSNs)-based organic/inorganic hybrid nanocarriers loading 5-Fluorouracil for the treatment of colon cancer with improved anticancer efficacy | |
| Kim et al. | Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle | |
| Zhang et al. | Multifunctional tumor-targeted PLGA nanoparticles delivering Pt (IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance | |
| CN103083239A (zh) | 一种蟾毒灵脂质体及其制备方法和应用 | |
| Groer et al. | Intratumoral cancer chemotherapy with a carrier-based immunogenic cell-death eliciting platinum (IV) Agent | |
| Deng et al. | Novel T7-modified pH-responsive targeted nanosystem for co-delivery of docetaxel and curcumin in the treatment of esophageal cancer | |
| Song et al. | Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of αvβ3-ligand binding | |
| AbouSamra | Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications | |
| Qian et al. | Evaluation of cisplatin-hydrogel for improving localized antitumor efficacy in gastric cancer | |
| WO2004053067A2 (en) | Methods for inhibiting cancer and scar formation | |
| Li et al. | Ultralong circulating choline phosphate liposomal nanomedicines for cascaded chemo-radiotherapy | |
| CN109200292B (zh) | 具有治疗阿尔茨海默病功效的纳米复合体及其制备方法与应用 | |
| US10537531B2 (en) | Casein coated drug-loaded iron oxide nanoparticles | |
| Lu et al. | Nanoparticle-based therapeutics to overcome obstacles in the tumor microenvironment of hepatocellular carcinoma | |
| CN114222580B (zh) | 一种预防和/或治疗卵巢癌的多肽药物及其用途 | |
| CN110974804B (zh) | p53信使RNA纳米粒及其制备方法和在制备治疗肿瘤药物中的应用 | |
| Zhao et al. | Autophagy modulation and synergistic therapy to Combat Multidrug resistance breast Cancer using hybrid cell membrane nanoparticles | |
| CN106267238A (zh) | 一种金属富勒烯复合物及其制备方法与应用 | |
| Zhou et al. | Reshaped local and systemic immune responses triggered by a biomimetic multifunctional nanoplatform coordinating multi-pathways for cancer therapy |